- Home
- Equipment
- north america
- gene therapy viral vectors
Refine by
Gene Therapy Viral Vectors Equipment Supplied In North America
6 equipment items found
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Perform consistent and compliant biotherapeutics characterization faster than ever. With the PA 800 Plus system, you can confidently safeguard the success of your biologics. Run multiple characterizations from a single system that biopharma labs depend on, and produce qualitative and quantitative analyses, with speed and ...
Manufactured by:G-CON Manufacturing, Inc. based inCollege Station, TEXAS (USA)
RECOMMENDED FOR Any medicinal drug or medical device application (upstream/ downstream processing, formulation, filling, packaging, gene/viral vector ...
Manufactured by:G-CON Manufacturing, Inc. based inCollege Station, TEXAS (USA)
RECOMMENDED FOR Any medicinal drug or medical device application (upstream/ downstream processing, formulation, filling, packaging, gene/viral vector ...
by:Expression Systems, LLC based inDavis, CALIFORNIA (USA)
ESF AF™ Insect Cell Culture Medium is an Animal Origin-Free formulation and is a complete serum-free, protein-free medium developed for robust cell growth, protein expression and baculovirus vector production for a wide range of insect cells including Sf9, Sf21, Tni, and Drosophila S2. ESF AF medium is comparable to ESF 921 for growth and expression. ESF AF contains L-Glutamine and ...
by:Dyno Therapeutics based inWatertown, MASSACHUSETTS (USA)
Our CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion and manufacturability. By building a massive and detailed map of synthetic AAV capsid sequence space, we can quickly navigate the landscape to find enhanced gene therapy vectors with ...
by:Neurona Therapeutics based inSouth San Francisco, CALIFORNIA (USA)
Neurona’s lead product candidate, NRTX-1001, comprises human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001’s first indication is for the treatment of drug-resistant focal epilepsy, which is a major unmet need affecting approximately one-third of people living with epilepsy. Epileptic seizures are characterized by imbalanced neural activity ...